Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Outcomes Therapy

Date: Monday, November 6, 2017

Time: 2:30PM-4:00PM

Meeting: 2017 ACR/ARHP Annual Meeting

2:30PM-4:00PM: Abstract Number: 1825

Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis

2:30PM-4:00PM: Abstract Number: 1821

Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study

2:30PM-4:00PM: Abstract Number: 1824

Evaluation of Pneumococcal and Tetanus Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy

2:30PM-4:00PM: Abstract Number: 1823

Methotrexate Requires High Serum BAFF Levels to Prevent Immunization Against TNF-α Inhibitors

2:30PM-4:00PM: Abstract Number: 1820

Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years

2:30PM-4:00PM: Abstract Number: 1822

The Effect of Sarilumab in Combination with Dmards on Fasting Glucose and Glycosylated Hemoglobin in Patients with Rheumatoid Arthritis with and without Diabetes

« View all sessions from this meeting